Product designer Henry F. Fabian Jr., MD, MBA, will provide demonstrations in booth 3515.
RODIN represents evidenced-based, superior clinical results that surgeons and patients demand.
DALLAS (PRWEB)
September 29, 2021
CTL Amedica Corporation will unveil its RODIN™ Transforaminal Expandable Lumbar Interbody Fusion System during the North American Spine Society (NASS) annual meeting and exhibition Sept. 29-Oct. 2, 2021. The largest spine meeting and exhibition in the world, NASS will be held at the Boston Convention and Exhibition Center, located at 415 Summer Street. CTL Amedica representatives will be available in booth 3515 to answer questions about RODIN™ and the full line of CTL Amedica products. RODIN’s™ product designer – Henry F. Fabian Jr., MD, MBA – will be doing in-booth demonstrations at 3 pm on Sept. 29 and at 9:30 am on Sept. 30.
FDA-cleared and in beta launch at CTL Amedica, RODIN™ is a horizontally expandable, minimally invasive interbody implant made of titanium. It has superior biomechanics, surface area and graft volume capacity, all with a simplified delivery system. At a 6mm cross-sectional width, non-deployed, it offers one of the smallest collapsed footprints of any expandable on the market. With its horizontally expanding capabilities, convex surfaces and lordotic offerings, the RODIN™ accomplishes a stable and impressive ALIF footprint through an MIS posterior approach.
“RODIN™ represents evidenced-based, superior clinical results that surgeons and patients demand,” said Dr. Fabian. “RODIN™ is designed to accommodate a wide range of patient anatomies and surgical preferences. Using RODIN™, the surgeon can accomplish an ALIF footprint through an MIS posterior approach, which gives the surgeon all the biomechanical advantages of the ALIF – anterior column support, better mechanics, more bone graft volume, more surface area and higher fusion rates – all without the need to go anterior, and we have the outcome data to prove it.”
CTL Amedica will launch RODIN™ with a long term (> 10-year follow-up) clinical series with a 98.5% clinical and radiographic fusion rate and an animal study showing 100% fusion throughout the entire series, with post study CT scan and histologic confirmation. Dr. Fabian has implanted the product in multiple surgeries with excellent results.
A skilled spine surgeon, Dr. Fabian has been in private practice for a number of years and has served as the team physician for several prominent organizations, including the U.S. Ski Association Men’s Alpine Ski Team, Steamboat Springs Winter Sports Club, Cleveland Crunch National Pro Soccer League and Cleveland Lumberjacks IHL Pro League. Dr. Fabian holds a bachelor’s degree in biomedical engineering from Case Western Reserve University, a master’s degree in biomedical engineering from Ohio State, an MD from the Medical College of Ohio and an executive MBA from Ohio State. He also completed an internship in general surgery and a residency in orthopaedic surgery at St. Luke’s Medical Center; as well as a fellowship in adult and pediatric reconstructive spine surgery at The Colorado Spine Center/Rocky Mountain Spine Clinic and an international training fellowship in internal fixation at Medizinische Hochschule Hannover Unfall Klinik in Hannover, Germany.
CTL Amedica is a forward-thinking medical device design, development and manufacturing company. CTL Amedica maintains a Texas-based headquarters and in-house manufacturing facility, along with a Pennsylvania-based R&D Center of Excellence. A leader in the medical device technology and biomaterials space, CTL Amedica provides a full line of cervical, thoracic and lumbar fusion and fixation products. In addition, it is the world’s exclusive provider of silicon nitride spine products. Silicon nitride demonstrates unique bacteriostatic properties, provides superior imaging across all modalities and promotes an enhanced osteogenic response. For more information, visit https://www.ctlamedica.com/.
Share article on social media or email: